1. US FDA Guidance

   • Paul Kind

   Editorial 23 December 2012 Pages: 833 - 836

2. Accuracy versus Transparency in Pharmacoeconomic Modelling

   • David M. Eddy

   Current Opinion 23 December 2012 Pages: 837 - 844

3. The Value of Thinly Spread QALYs

   • Duncan Mortimer

   Current Opinion 23 December 2012 Pages: 845 - 853

   

4. Using Discrete Choice Experiments within a Cost-Benefit Analysis Framework

   • Emma McIntosh

   Leading Article 23 December 2012 Pages: 855 - 868

   

5. Cost-of-Illness Studies

   • Ebere Akobundu
   • Jing Ju
   • C. Daniel Mullins

   Review Article 23 December 2012 Pages: 869 - 890

   

6. Impacts of Cost Containment Strategies on Pharmaceutical Expenditures of the National Health Insurance in Taiwan, 1996–2003

   • Yue-Chune Lee
   • Ming-Chin Yang
   • Sun-Bing Chen

   Original Research Article 23 December 2012 Pages: 891 - 902

   

7. Public Funding of Bosentan for the Treatment of Pulmonary Artery Hypertension in Australia

   • John H. Wlodarczyk
   • Leslie G. Cleland
   • Trevor J. Williams

   Original Research Article 23 December 2012 Pages: 903 - 915

   

8. Missing Data Imputation in Quality-of-Life Assessment

   • Ting Hsiang Lin

   Original Research Article 23 December 2012 Pages: 917 - 925

   

9. Modelling Lifetime Metabolic Progression and Cost Effectiveness of Treatment Strategies for Type 2 Diabetes

   • Andrew J. Palmer
   • Craig J. Currie

   Correspondence 23 December 2012 Pages: 927 - 929

10. The Authors’ Reply

    • Adrian A. Bagust
    • Marc Evans
    • Gonzalo Paris

    Correspondence 23 December 2012 Pages: 929 - 935